{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:58:10Z","timestamp":1788404290167,"version":"build-2803163510"},"reference-count":143,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Volkswagen Foundation (Lichtenberg program)","award":["PROGRESS"],"award-info":[{"award-number":["PROGRESS"]}]},{"name":"DZHK (German Research Centre for Cardiovascular Research)","award":["PROGRESS"],"award-info":[{"award-number":["PROGRESS"]}]},{"name":"ERA PerMed 2020 JTC","award":["PROGRESS"],"award-info":[{"award-number":["PROGRESS"]}]},{"name":"SFB1366\/2 (project B08)","award":["PROGRESS"],"award-info":[{"award-number":["PROGRESS"]}]},{"name":"DZHK partner site Mannheim\/Heidelberg","award":["PROGRESS"],"award-info":[{"award-number":["PROGRESS"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Platelets are important cellular targets in cardiovascular disease. Based on insights from basic science, translational approaches and clinical studies, a distinguished anti-platelet drug treatment regimen for cardiovascular patients could be established. Furthermore, platelets are increasingly considered as cells mediating effects \u201cbeyond thrombosis\u201d, including vascular inflammation, tissue remodeling and healing of vascular and tissue lesions. This review has its focus on the functions and interactions of platelets with potential translational and clinical relevance. The role of platelets for the development of atherosclerosis and therapeutic modalities for primary and secondary prevention of atherosclerotic disease are addressed. Furthermore, novel therapeutic options for inhibiting platelet function and the use of platelets in regenerative medicine are considered.<\/jats:p>","DOI":"10.3390\/ijms24076280","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T06:46:19Z","timestamp":1679899579000},"page":"6280","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Novel Aspects Targeting Platelets in Atherosclerotic Cardiovascular Disease\u2014A Translational Perspective"],"prefix":"10.3390","volume":"24","author":[{"given":"Aydin","family":"Huseynov","sequence":"first","affiliation":[{"name":"Department of Medicine, Cardiology, Angiology, Hemostasis and Intensive Care Medicine, University Medical Center Mannheim, Faculty of Medicine Mannheim, University of Heidelberg, 68135 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Reinhardt","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cardiology, Angiology, Hemostasis and Intensive Care Medicine, University Medical Center Mannheim, Faculty of Medicine Mannheim, University of Heidelberg, 68135 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Chandra","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cardiology, Angiology, Hemostasis and Intensive Care Medicine, University Medical Center Mannheim, Faculty of Medicine Mannheim, University of Heidelberg, 68135 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"D\u00fcrschmied","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cardiology, Angiology, Hemostasis and Intensive Care Medicine, University Medical Center Mannheim, Faculty of Medicine Mannheim, University of Heidelberg, 68135 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald F.","family":"Langer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cardiology, Angiology, Hemostasis and Intensive Care Medicine, University Medical Center Mannheim, Faculty of Medicine Mannheim, University of Heidelberg, 68135 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"ref_1","unstructured":"WHO (2019). World Health Organization cardiovascular disease risk charts: Revised models to estimate risk in 21 global regions. Lancet Glob. Health, 7, e1332\u2013e1345."},{"key":"ref_2","unstructured":"GBD 2017 Causes of Death Collaborators (2018). Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 392, 1736\u20131788."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","article-title":"The changing landscape of atherosclerosis","volume":"592","author":"Libby","year":"2021","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.jacc.2018.08.2147","article-title":"Macrophage Trafficking, Inflammatory Resolution, and Genomics in Atherosclerosis: JACC Macrophage in CVD Series (Part 2)","volume":"72","author":"Moore","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00062752-200701000-00011","article-title":"Intertwining of thrombosis and inflammation in atherosclerosis","volume":"14","author":"Croce","year":"2007","journal-title":"Curr. Opin. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jacc.2019.07.061","article-title":"From Focal Lipid Storage to Systemic Inflammation: JACC Review Topic of the Week","volume":"74","author":"Libby","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa1605086","article-title":"Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease","volume":"375","author":"Khera","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_11","first-page":"757","article-title":"Review. Leukocyte and endothelial cell adhesion molecules in inflammation focusing on inflammatory heart disease","volume":"21","author":"Golias","year":"2007","journal-title":"Vivo"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.106.676890","article-title":"Subendothelial lipoprotein retention as the initiating process in atherosclerosis: Update and therapeutic implications","volume":"116","author":"Tabas","year":"2007","journal-title":"Circulation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nature00804","article-title":"Subendothelial retention of atherogenic lipoproteins in early atherosclerosis","volume":"417","author":"Skalen","year":"2002","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1161\/ATVBAHA.108.179697","article-title":"Oxidized low-density lipoprotein and atherosclerosis","volume":"30","author":"Steinberg","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1055\/s-2007-995851","article-title":"Atherosclerosis: Coagulation and fibrinolysis","volume":"24","author":"Sueishi","year":"1998","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jacc.2012.01.023","article-title":"Counterregulation rules in atherothrombosis","volume":"59","author":"Libby","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.jacc.2011.12.033","article-title":"Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction","volume":"59","author":"Leibundgut","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.31083\/j.rcm2302073","article-title":"Biomarkers of endothelial activation and dysfunction in cardiovascular diseases","volume":"23","author":"Zhang","year":"2022","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/CIRCULATIONAHA.106.652859","article-title":"Endothelial function and dysfunction: Testing and clinical relevance","volume":"115","author":"Deanfield","year":"2007","journal-title":"Circulation"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/cvr\/cvaa085","article-title":"Endothelial function in cardiovascular medicine: A consensus paper of the European Society of Cardiology Working Groups on Atherosclerosis and Vascular Biology, Aorta and Peripheral Vascular Diseases, Coronary Pathophysiology and Microcirculation, and Thrombosis","volume":"117","author":"Alexander","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41569-019-0239-5","article-title":"Endothelial responses to shear stress in atherosclerosis: A novel role for developmental genes","volume":"17","author":"Souilhol","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.pcad.2016.04.003","article-title":"Coronary Atherosclerosis: Pathophysiologic Basis for Diagnosis and Management","volume":"58","author":"Boudoulas","year":"2016","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1161\/CIRCULATIONAHA.118.038571","article-title":"Caveolin-1 Regulates Atherogenesis by Attenuating Low-Density Lipoprotein Transcytosis and Vascular Inflammation Independently of Endothelial Nitric Oxide Synthase Activation","volume":"140","author":"Ramirez","year":"2019","journal-title":"Circulation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1161\/ATVBAHA.114.303863","article-title":"alpha5beta1 integrin signaling mediates oxidized low-density lipoprotein-induced inflammation and early atherosclerosis","volume":"34","author":"Yurdagul","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1161\/CIRCRESAHA.109.216283","article-title":"Atheroprone hemodynamics regulate fibronectin deposition to create positive feedback that sustains endothelial inflammation","volume":"106","author":"Feaver","year":"2010","journal-title":"Circ. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCRESAHA.117.310795","article-title":"Circulating Platelets as Mediators of Immunity, Inflammation, and Thrombosis","volume":"122","author":"Koupenova","year":"2018","journal-title":"Circ. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"548631","DOI":"10.3389\/fimmu.2020.548631","article-title":"Platelets as Mediators of Neuroinflammation and Thrombosis","volume":"11","author":"Rawish","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1111\/bph.15476","article-title":"Complement, inflammation and thrombosis","volume":"178","author":"Rawish","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1161\/CIRCRESAHA.114.302721","article-title":"Mechanisms of plaque formation and rupture","volume":"114","author":"Bentzon","year":"2014","journal-title":"Circ. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.blre.2011.03.002","article-title":"Platelets at work in primary hemostasis","volume":"25","author":"Broos","year":"2011","journal-title":"Blood Rev."},{"key":"ref_33","unstructured":"Farndale, R.W., Siljander, P.R., Onley, D.J., Sundaresan, P., Knight, C.G., and Barnes, M.J. (2003). Biochemical Society Symposia, Portland Press."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/nm1102-1227","article-title":"Platelets in atherothrombosis","volume":"8","author":"Ruggeri","year":"2002","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra040403","article-title":"Treatment of von Willebrand\u2019s Disease","volume":"351","author":"Mannucci","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3109\/09537104.2015.1049519","article-title":"The future of P2Y12 receptor antagonists","volume":"26","author":"Thomas","year":"2015","journal-title":"Platelets"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-0035-1564835","article-title":"Platelet Physiology","volume":"42","author":"Gremmel","year":"2016","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1093\/eurheartj\/ehr373","article-title":"Antiplatelet agents for the treatment and prevention of atherothrombosis","volume":"32","author":"Patrono","year":"2011","journal-title":"Eur. Heart J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Davi","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1161\/01.RES.0000251742.71301.16","article-title":"Activation of platelet function through G protein-coupled receptors","volume":"99","author":"Offermanns","year":"2006","journal-title":"Circ. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1172\/JCI7569","article-title":"A revised model of platelet aggregation","volume":"105","author":"Kulkarni","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4A","DOI":"10.1016\/j.amjcard.2008.11.017","article-title":"Role of platelets in atherothrombosis","volume":"103","author":"Jennings","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1161\/hq0202.104122","article-title":"Platelet shape changes and adhesion under high shear flow","volume":"22","author":"Kuwahara","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4065\/81.1.59","article-title":"Platelets in atherothrombosis","volume":"81","author":"Vorchheimer","year":"2006","journal-title":"Mayo Clin. Proc."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/10739680590925493","article-title":"Endogenous mechanisms of inhibition of platelet function","volume":"12","author":"Jin","year":"2005","journal-title":"Microcirculation"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/01.CIR.92.3.657","article-title":"Coronary plaque disruption","volume":"92","author":"Falk","year":"1995","journal-title":"Circulation"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(89)90953-7","article-title":"Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques","volume":"2","author":"Richardson","year":"1989","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.pharmthera.2006.08.005","article-title":"From pathophysiology to targeted therapy for atherothrombosis: A role for the combination of statin and aspirin in secondary prevention","volume":"113","author":"Chapman","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"8295054","DOI":"10.1155\/2019\/8295054","article-title":"Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review","volume":"2019","author":"Bauersachs","year":"2019","journal-title":"Cardiovasc. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.atherosclerosis.2012.04.007","article-title":"\u201cIn vivo\u201d imaging of atherosclerosis","volume":"224","author":"Gallino","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2009.10.009","article-title":"An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide","volume":"209","author":"McAteer","year":"2010","journal-title":"Atherosclerosis"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fcvm.2020.00119","article-title":"Advances in IVUS\/OCT and Future Clinical Perspective of Novel Hybrid Catheter System in Coronary Imaging","volume":"7","author":"Ono","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jacc.2008.05.051","article-title":"A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease","volume":"52","author":"Schomig","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1161\/CIRCULATIONAHA.104.521864","article-title":"Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: A meta-analysis","volume":"111","author":"Katritsis","year":"2005","journal-title":"Circulation"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"g3859","DOI":"10.1136\/bmj.g3859","article-title":"Revascularisation versus medical treatment in patients with stable coronary artery disease: Network meta-analysis","volume":"348","author":"Windecker","year":"2014","journal-title":"BMJ"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/ejcts\/ezr213","article-title":"Propensity matched analysis of bilateral internal mammary artery versus single left internal mammary artery grafting at 17-year follow-up: Validation of a contemporary surgical experience","volume":"41","author":"Grau","year":"2012","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/HCO.0b013e32833f0498","article-title":"Prevalence and variability of internal mammary graft use in contemporary multivessel coronary artery bypass graft","volume":"25","author":"Schmitto","year":"2010","journal-title":"Curr. Opin. Cardiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/j.jacc.2013.04.007","article-title":"One-stop hybrid coronary revascularization versus coronary artery bypass grafting and percutaneous coronary intervention for the treatment of multivessel coronary artery disease: 3-year follow-up results from a single institution","volume":"61","author":"Shen","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jcin.2014.05.025","article-title":"Hybrid revascularization for multivessel coronary artery disease","volume":"7","author":"Gasior","year":"2014","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1093\/eurheartj\/eht059","article-title":"The rationale for Heart Team decision-making for patients with stable, complex coronary artery disease","volume":"34","author":"Head","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ahj.2017.12.006","article-title":"ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes","volume":"198","author":"Bowman","year":"2018","journal-title":"Am. Heart J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): A randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis","volume":"321","author":"Zheng","year":"2019","journal-title":"JAMA"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12933-019-0875-4","article-title":"Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: Updated literature-based and individual participant data meta-analyses of randomized controlled trials","volume":"18","author":"Seidu","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Antithrombotic Trialists\u2019 (ATT) Collaboration, Baigent, C., Blackwell, L., Collins, R., Emberson, J., Godwin, J., Peto, R., Buring, J., Hennekens, C., and Kearney, P. (2009). Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet, 373, 1849\u20131860.","DOI":"10.1016\/S0140-6736(09)60503-1"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"CAPRIE Steering Committee (1996). A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 348, 1329\u20131339.","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/S0140-6736(20)30315-9","article-title":"Monotherapy with a P2Y(12) inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: A systematic review and meta-analysis","volume":"395","author":"Chiarito","year":"2020","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2016.12.011","article-title":"Effect of sarpogrelate, a selective 5-HT(2A) receptor antagonist, on characteristics of coronary artery disease in patients with type 2 diabetes","volume":"257","author":"Lee","year":"2017","journal-title":"Atherosclerosis"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1161\/STROKEAHA.107.505131","article-title":"Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial","volume":"39","author":"Shinohara","year":"2008","journal-title":"Stroke"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1161\/CIRCULATIONAHA.118.033942","article-title":"Platelet Serotonin Aggravates Myocardial Ischemia\/Reperfusion Injury via Neutrophil Degranulation","volume":"139","author":"Mauler","year":"2019","journal-title":"Circulation"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.2165\/11640880-000000000-00000","article-title":"The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: From aspirin to the present day","volume":"72","author":"Angiolillo","year":"2012","journal-title":"Drugs"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.jacc.2018.09.057","article-title":"ACC\/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison","volume":"72","author":"Capodanno","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","article-title":"2016 ACC\/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF\/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF\/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA\/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC\/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery","volume":"134","author":"Levine","year":"2016","journal-title":"Circulation"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1161\/STROKEAHA.120.033033","article-title":"Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient Ischemic Attack: Meta-Analysis of Randomized Controlled Trials","volume":"52","author":"Bhatia","year":"2021","journal-title":"Stroke"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents","volume":"334","author":"Schomig","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators","volume":"339","author":"Leon","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1161\/01.CIR.98.16.1597","article-title":"Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study","volume":"98","author":"Bertrand","year":"1998","journal-title":"Circulation"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1161\/01.CIR.98.20.2126","article-title":"Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS)","volume":"98","author":"Urban","year":"1998","journal-title":"Circulation"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","article-title":"Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS)","volume":"102","author":"Bertrand","year":"2000","journal-title":"Circulation"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): A randomised factorial trial","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJMoa1001266","article-title":"Duration of dual antiplatelet therapy after implantation of drug-eluting stents","volume":"362","author":"Park","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(13)61451-8","article-title":"Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: A secondary, prespecified analysis of the TRILOGY ACS trial","volume":"382","author":"Wiviott","year":"2013","journal-title":"Lancet"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1016\/j.jacc.2014.08.053","article-title":"Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: The ACCOAST-PCI study","volume":"64","author":"Montalescot","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: A randomized, controlled trial","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: A randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting","volume":"36","author":"Byrne","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1161\/CIRCULATIONAHA.116.024823","article-title":"Prasugrel Versus Ticagrelor in Patients with Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study","volume":"134","author":"Motovska","year":"2016","journal-title":"Circulation"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jcin.2017.04.019","article-title":"Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation","volume":"10","author":"Nakamura","year":"2017","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): A randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes","volume":"381","author":"Schupke","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/jamacardio.2021.0475","article-title":"Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial","volume":"6","author":"Mayer","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"107630","DOI":"10.1016\/j.pharmthera.2020.107630","article-title":"Glycoprotein VI - novel target in antiplatelet medication","volume":"217","author":"Borst","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/1074248419899314","article-title":"Novel Antiplatelet Agents in Cardiovascular Disease","volume":"25","author":"Tscharre","year":"2020","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12265-012-9435-y","article-title":"Novel antiplatelet agents: ALX-0081, a Nanobody directed towards von Willebrand factor","volume":"6","author":"Bartunek","year":"2013","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1182\/blood-2004-02-0534","article-title":"Reciprocal cross-talk between P2Y1 and P2Y12 receptors at the level of calcium signaling in human platelets","volume":"104","author":"Hardy","year":"2004","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"6150","DOI":"10.1021\/jm5006226","article-title":"Discovery of 4-aryl-7-hydroxyindoline-based P2Y1 antagonists as novel antiplatelet agents","volume":"57","author":"Yang","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11239-015-1302-7","article-title":"The P2Y1 receptor antagonist MRS2500 prevents carotid artery thrombosis in cynomolgus monkeys","volume":"41","author":"Wong","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1161\/ATVBAHA.115.306885","article-title":"Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis","volume":"36","author":"Gremmel","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1093\/eurheartj\/ehz542","article-title":"Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1beta inhibition with canakinumab: Further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis","volume":"41","author":"Ridker","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood-2018-11-882993","article-title":"Thromboinflammation: Challenges of therapeutically targeting coagulation and other host defense mechanisms","volume":"133","author":"Jackson","year":"2019","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.blre.2006.06.001","article-title":"Platelet-neutrophil-interactions: Linking hemostasis and inflammation","volume":"21","author":"Zarbock","year":"2007","journal-title":"Blood Rev."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/FJC.0000000000000233","article-title":"First-in-Man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin","volume":"65","author":"Schmitt","year":"2015","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1182\/blood-2018-03-841593","article-title":"Platelet-derived TLT-1 is a prognostic indicator in ALI\/ARDS and prevents tissue damage in the lungs in a mouse model","volume":"132","author":"Deal","year":"2018","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1177\/1076029618774149","article-title":"High Levels of Soluble Triggering Receptor Expressed on Myeloid Cells-Like Transcript (TLT)-1 Are Associated With Acute Respiratory Distress Syndrome","volume":"24","author":"Rondina","year":"2018","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood-2017-06-788067","article-title":"Platelet glycoprotein VI aids in local immunity during pneumonia-derived sepsis caused by gram-negative bacteria","volume":"131","author":"Claushuis","year":"2018","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1615\/CritRevImmunol.v37.i2-6.100","article-title":"Functions of CD40 and Its Ligand, gp39 (CD40L)","volume":"37","author":"Laman","year":"2017","journal-title":"Crit. Rev. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"825892","DOI":"10.3389\/fimmu.2022.825892","article-title":"Platelets as Key Factors in Inflammation: Focus on CD40L\/CD40","volume":"13","author":"Cognasse","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.08.004","article-title":"Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy","volume":"193","author":"Knowles","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Katsanos, K., Spiliopoulos, S., Saha, P., Diamantopoulos, A., Karunanithy, N., Krokidis, M., Modarai, B., and Karnabatidis, D. (2015). Comparative Efficacy and Safety of Different Antiplatelet Agents for Prevention of Major Cardiovascular Events and Leg Amputations in Patients with Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0135692"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.5551\/jat.ED054","article-title":"Antiplatelet Drugs and Endothelial Function","volume":"23","author":"Higashi","year":"2016","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000089355","article-title":"Platelets, inflammation, and atherothrombotic neurovascular disease: The role of endothelial dysfunction","volume":"20","author":"Blanco","year":"2005","journal-title":"Cerebrovasc. Dis."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1161\/01.HYP.0000034745.98129.EC","article-title":"Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release","volume":"40","author":"Kalinowski","year":"2002","journal-title":"Hypertension"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1042\/CS20180306","article-title":"Atherosclerosis and inflammation: Overview and updates","volume":"132","author":"Geovanini","year":"2018","journal-title":"Clin. Sci."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1161\/01.CIR.102.8.820","article-title":"Cardiovascular benefit of cholesterol-lowering therapy: Does improved endothelial vasodilator function matter?","volume":"102","author":"Cannon","year":"2000","journal-title":"Circulation"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/bcp.12826","article-title":"P2Y12 receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation","volume":"81","author":"Chan","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Everts, P., Onishi, K., Jayaram, P., Lana, J.F., and Mautner, K. (2020). Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020. Int. J. Mol. Sci., 21.","DOI":"10.20944\/preprints202010.0069.v1"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11684-017-0551-6","article-title":"Platelet-rich plasma: Combinational treatment modalities for musculoskeletal conditions","volume":"12","author":"Andia","year":"2018","journal-title":"Front. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/08977190600821327","article-title":"Platelet-rich plasma preparation using three devices: Implications for platelet activation and platelet growth factor release","volume":"24","author":"Everts","year":"2006","journal-title":"Growth Factors"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1051\/ject\/200638174","article-title":"Platelet-rich plasma and platelet gel: A review","volume":"38","author":"Everts","year":"2006","journal-title":"J. Extra Corpor. Technol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00008505-200110000-00002","article-title":"Platelet-rich plasma (PRP): What is PRP and what is not PRP?","volume":"10","author":"Marx","year":"2001","journal-title":"Implant Dent."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10815-021-02146-9","article-title":"A narrative review of platelet-rich plasma (PRP) in reproductive medicine","volume":"38","author":"Sharara","year":"2021","journal-title":"J. Assist. Reprod. Genet."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1517\/14712598.2015.1038234","article-title":"Platelet-rich plasma in the treatment of skeletal muscle injuries","volume":"15","author":"Andia","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1007\/s11999-015-4179-z","article-title":"Platelet-rich plasma modulates the secretion of inflammatory\/angiogenic proteins by inflamed tenocytes","volume":"473","author":"Andia","year":"2015","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/17474086.2021.1860002","article-title":"Evidence-based indications of platelet-rich plasma therapy","volume":"14","author":"Gupta","year":"2021","journal-title":"Expert Rev. Hematol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/7\/6280\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:03:57Z","timestamp":1760123037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/7\/6280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":143,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ijms24076280"],"URL":"https:\/\/doi.org\/10.3390\/ijms24076280","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]}}}